South Dakota Cannabis Market Analysis: 104 Establishments, ~18% Modeled Capture, and Strong Evidence That Market Structure Matters

South Dakota and North Dakota are, for cannabis-policy purposes, close to a matched pair: nearly identical Republican supermajorities, nearly identical median income and education, nearly identical rejection of adult-use legalization, and populations within 17% of each other. South Dakota's medical program still enrolls roughly double North Dakota's patient count per capita — 19,383 patients and still adding more than a thousand since February, against North Dakota's plateaued ~10,300 — while running at an estimated ~18% modeled capture of resident demand against North Dakota's ~11%, and doing it with flower that tests stronger and sells for a fraction of North Dakota's price. Politics, income, education, and sentiment toward recreational cannabis are all a wash between the two states. What differs is that North Dakota wrote a two-producer, eight-store cap into statute, and South Dakota didn't — and the comparison provides unusually strong evidence that this is what's driving the gap.

Market Overview

South Dakota made cannabis history in November 2020 by passing medical and adult-use legalization on the same ballot — the only state ever to pass both on the same ballot. Initiated Measure 26 (medical) passed 69.92% in favor. Constitutional Amendment A (adult-use) passed too, 54.18%. Governor Kristi Noem directed a legal challenge against Amendment A on single-subject grounds; a circuit judge struck it down in February 2021, and the state Supreme Court upheld that ruling in November 2021. Amendment A never took effect — adult-use was overturned by courts, not by voters.

The medical law took effect July 1, 2021, and the first cannabis sales in the state began that same month — but at the Flandreau Santee Sioux Tribe's sovereign Native Nations Cannabis operation, roughly 45 miles from Sioux Falls, not a state-licensed store. The first state-licensed dispensary, Unity Road in Hartford, didn't open until July 27, 2022, a full year later.

Unlike North Dakota's statutory caps, South Dakota's enabling law set no hard limit on the number of dispensaries, cultivators, or manufacturers. The state establishment list shows the result: 60 dispensaries, 29 cultivators, 14 manufacturers, and 1 testing lab — 104 licensed establishments total. That figure represents certified establishments rather than confirmed operating storefronts; South Dakota's own SFY2024 report notes some certified establishments have closed while others "have not gotten off the ground to become operational," so the true count of active stores may run modestly below 60 — which would mean the density and revenue-per-store figures below are a slight overstatement and understatement, respectively. The SFY2024 annual report's own establishment donut chart showed a somewhat different mix at that point in time (68/35/19/2) — establishment counts move between snapshots, consistent with normal consolidation. Every reading, current or historical, places the total in the same range: a market an order of magnitude larger than North Dakota's statutory 2 and 8. Genesis Farms is the closest thing the state has to a dominant operator — 14 of the 60 dispensary listings (23%), including five in Rapid City — the largest single footprint in the market but well short of anything resembling the near-total control a two-producer state produces by definition.

Key metrics (June 2026, per the program's monthly and SFY2024 annual reporting):

• Active patients: 19,383, up from an estimated 13,755 at the SFY2024 year-end (derived from the report's 10,001 severe-pain patients representing 72.71% of the total) — and per the program's own monthly releases, up more than 1,000 since February 2026 (18,036 in February)
• Caregivers: 601; certifying providers: 207 (117 physicians, 72 advanced practice RNs, 18 physician assistants)
• Top qualifying conditions: severe/debilitating pain (70.4%), PTSD (13.9%), severe/persistent muscle spasms (4.2%)
• 18,805 resident cardholders, 572 nonresident (these sum to 19,377 against the reported 19,383 active total — a small gap likely reflecting a snapshot-date difference across the dashboard's panels) — approximately 97% resident, 3% nonresident
• Home cultivation: permitted in limited form — 777 patients (4.0%) hold an adult, caregiver, or locked-facility cultivation authorization (an additional 17 patients fall in an "unknown" cultivation-type category not counted here as confirmed authorizations); North Dakota permits none at all
• SFY2024 program finances: $1,915,946 total revenue ($1,141,176 cardholder fees, $774,770 establishment fees) against $1,193,010 in expenses — a fee-funded regulator, not a sales-tax-funded one

The Matched-Pair Comparison

The reason South Dakota's outperformance looks attributable to program design rather than culture, politics, or demographics is that essentially everything else about these two states is a wash.

Politics: both are Republican trifectas with veto-proof supermajorities in both chambers — South Dakota's Senate and House are each roughly 91% Republican; North Dakota's run in the high-80s to low-90s percent. Both rejected adult-use legalization in their most recent comparable votes, and South Dakota rejected it by a wider margin: 44.46–55.54 in 2024, against North Dakota's 47.45–52.55. Whatever is driving South Dakota's enrollment advantage, it isn't a more cannabis-friendly electorate.

Demographics: median household income ($75,081 vs. $76,657), poverty rate (10.4% vs. 11.1%), bachelor's degree attainment (31.9% vs. 32.7%), and labor force participation (66.7% vs. 67.4%) all sit within a few points. Both economies run on the same agricultural base. The one demographic axis where the states genuinely diverge — Native American population, 9.0% in South Dakota versus 5.4% in North Dakota — cuts against South Dakota's advantage rather than explaining it: the SFY2024 annual report's patient-race breakdown shows resident American Indian patients at 6% of the resident registry against a 9.0% population share, versus 89% and 82.3% for white residents — a rate roughly 1.6 times lower for American Indian residents than for white residents.

Part of that gap may be structural rather than a matter of demand, though the evidence available can't quantify how much. Native Nations Cannabis, owned and operated by the Flandreau Santee Sioux Tribe on sovereign land roughly 45 miles from Sioux Falls, opened to the public July 1, 2021, a year before any state-licensed dispensary existed, and operates under the tribe's own regulatory authority rather than the state's. It does not appear on the Department of Health's establishment list, and any sales there — to tribal members or otherwise — are invisible to the state patient registry this analysis and the state's own reporting are built on. Some of its customers may also hold state cards; the magnitude of any resulting undercount in the state's Native American patient figures is not something the available data can pin down. What's clear is that the registry cannot see this channel at all, so South Dakota's true legal-cannabis footprint is undercounted by at least this one operation.

One alternative explanation deserves a direct answer rather than a passing mention: North Dakota's 2025 legislative session expanded telehealth specifically because certifying-provider access was seen as constraining enrollment, raising the possibility that North Dakota's shortfall is a provider-supply problem rather than a retail-structure problem. The numbers argue against it. North Dakota's roughly 358 certifying providers against its ~580,000 adult population works out to about 61.7 providers per 100,000 adults; South Dakota's 207 providers against ~673,000 adults is about 30.8 per 100,000 — North Dakota has roughly double South Dakota's per-capita provider density. If certification access were the binding constraint, North Dakota's enrollment should be higher than South Dakota's, not less than half of it. Provider supply doesn't explain the gap; if anything, it makes North Dakota's underperformance harder to explain by anything other than retail structure.

Two nearly identical electorates, two nearly identical economies, and one program that enrolls at roughly double the rate. Some remaining variables — qualifying-condition lists, local zoning, program-implementation timing — could differ between the states in ways this analysis hasn't isolated. But the one difference documented at the statutory level, and the one the framework predicts should matter most, is how many licenses each legislature was willing to write into law.

Structural Comparison

South Dakota's dispensary density lands almost exactly at Mississippi's level — an uncapped, competitively licensed medical market landing at nearly identical structural density to another uncapped state, despite the two having nothing else in common regionally or demographically. North Dakota, on a comparable adult population, sits at roughly one-sixth South Dakota's density.

The supply side is where the gap becomes almost absurd. South Dakota's establishment list carries 29 cultivation and 14 manufacturing certificates — 43 certificates feeding those 60 stores, though some may belong to the same legal entity (Genesis Farms, for one, holds dispensary, cultivation, and manufacturing certificates), so 43 certificates isn't necessarily 43 separate companies. North Dakota's law, enacted in 2017, sets a default maximum of two manufacturers and eight dispensaries, with a legal provision allowing the state to license more "to increase access" that has gone unused for nine years. Whether South Dakota's true count of distinct operators is 43 or somewhat fewer, it is not two.

It's also not that South Dakota simply made access cheaper across the board. A South Dakota patient card costs $75 per year; North Dakota's 2025 legislation extended its card to two years at $40, an effective $20 annually — South Dakota patients pay roughly four times North Dakota's per-year fee and still enroll at double the rate. Whatever is driving the enrollment gap, it isn't that South Dakota made the front door cheaper. It made the market bigger.

Per-Patient Spend and Total Addressable Market (Framework-Modeled)

South Dakota does not publish aggregate dispensary sales — a genuine gap this section works around with modeled estimates rather than official figures, the same discipline applied consistently across this series. Every figure below should be read as framework-modeled, not observed market data.

The framework's standard demand model: Census Bureau estimates put South Dakota's population at 935,094 (Vintage 2025), with 23.5% under 18. Netting out an estimated 18–20 cohort using the same method applied to Iowa and North Dakota yields approximately 673,000 adults 21 and over. At the 18% participation baseline, that's roughly 121,000 consumers; at 1.0 gram per day, resident demand is approximately 44.2 million grams annually — approximately $243 million at the framework's normalized $5.50 per gram.

Per-patient annual spend has no direct sales figure to anchor to in South Dakota. In its place, this analysis uses the arithmetic mean of a band verified across five other states in this dataset with wildly different geography, pricing, and program age: Mississippi ($2,103/year), Hawaii ($2,228), North Dakota ($2,257), West Virginia ($2,642), and Arkansas ($2,646) — a $2,100–2,650/year cluster averaging $2,375. Applied to South Dakota's 18,805 resident patients (matching the resident-only TAM denominator): ~$44.7 million in modeled annual spend, or approximately 18% framework-modeled capture of the $243 million resident TAM — above every other capped or high-friction medical program in this dataset, while still adding patients faster than any of them.

The Potency and Pricing Audit (Point-in-Time)

A July 2026 audit of flower listings at Genesis Farms in Sioux Falls — 46 distinct strains, spot-checked by the author against two additional competitors with consistent results — shows a market North Dakota's duopoly structure cannot produce. Menu pricing and potency shift month to month at any dispensary; the figures below are a snapshot, not a permanent baseline, and the underlying listings have not been published as a standalone dataset, so the specific numbers should be read as a documented spot-check rather than an independently reproducible audit. The structural gap they illustrate — competitive segmentation versus duopoly uniformity — is the more durable claim.

• Mean THC 24.8%, median 24.5%, range 16.2–32.3%. Only 13% of listings test under 20%, against 59% in North Dakota's audited menus.
• Bulk ounce pricing runs $2.68–3.57/g at the value-to-mid tier, rising to $8.04/g for premium 25%+ flower — genuine price-by-quality segmentation. North Dakota's menus showed no such gradient: potency ranged 11–28% with no corresponding price tier, because two producers have no competitive reason to segment.
• At the $99.99/oz tier (~23.5% average THC, the most common ounce price point), the effective cost is about $0.0152 per milligram of THC — cheaper than the Florida comparison point used in the North Dakota analysis ($0.024/mg) and roughly a quarter of North Dakota's own bulk-tier price ($0.064/mg). This specific ratio is arithmetically sound regardless of how the broader sample is weighted, though it inherits any future revision to the North Dakota or Florida figures it's compared against.

The apparent price uniformity across South Dakota's competing dispensaries and North Dakota's two producers looks superficially similar — everyone charging about the same amount — but the mechanisms are opposite. In South Dakota, convergence is what competition produces: enough sellers chasing the same patients that prices get pushed down from below, with quality as the remaining axis of competition. In North Dakota, convergence is what the absence of competition produces: two producers with nowhere to be undercut from, and no quality segmentation because nothing forces it.

Even the single-gram tier — the format least sensitive to bulk-buying leverage — shows the gap. South Dakota's single grams ran $6.99–9.99 at 23–29% THC. North Dakota's single grams sat flat at $17 regardless of which end of its 11–28% range a patient bought into.

Tax Structure

South Dakota applies standard state sales tax — currently 4.2%, a temporary reduction from 4.5% scheduled to revert, plus up to 2% local — to medical cannabis purchases, with no cannabis-specific excise tax. The state has no personal income tax at all, one of the more aggressively low-friction tax regimes in the country even accounting for the sales tax's scheduled reversion. 2024's Senate Bill 43 raised the statutory ceiling on establishment fees to $20,000; the program's administrative rule then set the actual annual fee at $9,000. Patient cards cost $75 per year ($20 for low-income patients). Because South Dakota's sales-tax-funded reporting doesn't itemize cannabis receipts separately — unlike North Dakota's DHHS, which voluntarily reports total dispensary sales as a matter of administrative convention — the state's true market size is not a matter of public record anywhere in state government, a genuine transparency gap this analysis works around rather than one it can close.

The Bottom Line

North Dakota and South Dakota offer an unusually clean comparison, even if a two-state observational study can't fully rule out every confounder. Same electorate, same rejection of recreational legalization, same income bracket, same agricultural economy, same Republican trifecta with the same supermajority margins. One state capped its medical market at two producers and eight stores by a 2017 statute and has stayed there through seven years of dispensary operation, plateaued at roughly 10,300 patients and ~11% modeled capture, with double South Dakota's provider density and less than half its enrollment. The other let the market find its own equilibrium — 104 licensed establishments, real price-by-quality competition, flower testing meaningfully stronger at a quarter of the price — and is sitting at roughly double the enrollment and an estimated ~18% modeled capture, still growing faster than any capped program in this dataset manages once mature.

Nearly every variable that might otherwise explain the gap comes back a wash, or points the wrong direction. What's left, and what the evidence here is unusually well-suited to isolate, is the one thing these two states chose to do differently: how many licenses the legislature was willing to write into law. Pricing, density, and quality all move together in exactly the direction the Black Market Death Equation predicts, in a state that is otherwise, by nearly every measure that should matter, North Dakota's twin.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.